

HR 7658

To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: May 3, 2022

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (May 3, 2022)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/7658>

Sponsor

Name: Rep. O'Halleran, Tom [D-AZ-1]

Party: Democratic • **State:** AZ • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Lesko, Debbie [R-AZ-8]	R · AZ		May 3, 2022

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	May 3, 2022

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 4348	Related bill	Jul 13, 2022: Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
117 HR 7667	Related bill	Jun 9, 2022: Received in the Senate.
117 S 4152	Identical bill	May 5, 2022: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of May 3, 2022)

This bill reauthorizes through FY2027 the Food and Drug Administration's Critical Path Public-Private Partnerships, which support medical product innovation, development, and safety.

Actions Timeline

- May 3, 2022:** Introduced in House
- May 3, 2022:** Referred to the House Committee on Energy and Commerce.